194 related articles for article (PubMed ID: 37392863)
21. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
[TBL] [Abstract][Full Text] [Related]
22. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
23. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Noordermeer SM; van Attikum H
Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
[TBL] [Abstract][Full Text] [Related]
24. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
Chatterjee P; Choudhary GS; Alswillah T; Xiong X; Heston WD; Magi-Galluzzi C; Zhang J; Klein EA; Almasan A
Mol Cancer Ther; 2015 Aug; 14(8):1896-906. PubMed ID: 26026052
[TBL] [Abstract][Full Text] [Related]
25. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
[TBL] [Abstract][Full Text] [Related]
26. Rad51 recruitment and exclusion of non-homologous end joining during homologous recombination at a Tus/Ter mammalian replication fork barrier.
Willis NA; Panday A; Duffey EE; Scully R
PLoS Genet; 2018 Jul; 14(7):e1007486. PubMed ID: 30024881
[TBL] [Abstract][Full Text] [Related]
27. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
[TBL] [Abstract][Full Text] [Related]
29. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
30. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
31. RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments.
Hu Y; Raynard S; Sehorn MG; Lu X; Bussen W; Zheng L; Stark JM; Barnes EL; Chi P; Janscak P; Jasin M; Vogel H; Sung P; Luo G
Genes Dev; 2007 Dec; 21(23):3073-84. PubMed ID: 18003859
[TBL] [Abstract][Full Text] [Related]
32. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
33. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
Sinha S; Chatterjee S; Paul S; Das B; Dash SR; Das C; Kundu CN
Exp Cell Res; 2022 Nov; 420(1):113338. PubMed ID: 36075449
[TBL] [Abstract][Full Text] [Related]
34. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
Reilly NM; Yard BD; Pittman DL
Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
[TBL] [Abstract][Full Text] [Related]
35. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
36. Targeting RECQL5 Functions, by a Small Molecule, Selectively Kills Breast Cancer
Chakraborty S; Dutta K; Gupta P; Das A; Das A; Ghosh SK; Patro BS
J Med Chem; 2021 Feb; 64(3):1524-1544. PubMed ID: 33529023
[TBL] [Abstract][Full Text] [Related]
37. A variant of the breast cancer type 2 susceptibility protein (BRC) repeat is essential for the RECQL5 helicase to interact with RAD51 recombinase for genome stabilization.
Islam MN; Paquet N; Fox D; Dray E; Zheng XF; Klein H; Sung P; Wang W
J Biol Chem; 2012 Jul; 287(28):23808-18. PubMed ID: 22645136
[TBL] [Abstract][Full Text] [Related]
38. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Yang L; Zhang Y; Shan W; Hu Z; Yuan J; Pi J; Wang Y; Fan L; Tang Z; Li C; Hu X; Tanyi JL; Fan Y; Huang Q; Montone K; Dang CV; Zhang L
Sci Transl Med; 2017 Jul; 9(400):. PubMed ID: 28747513
[TBL] [Abstract][Full Text] [Related]
39. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
40. PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits.
Pauwels EKJ; Bourguignon MH
Med Princ Pract; 2022; 31(4):303-312. PubMed ID: 35636395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
